Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric
Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric
批准号:
8396082
负责人:
Cory Berkland
金额:
$21.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2013-09-30
关键词:
AddressAdultAgeBiocompatible Coated MaterialsBiological AssayCaliberChairpersonCharacteristicsChildChildhoodCitiesClinicalDevelopmentDiseaseDosage FormsDoseDrug Delivery SystemsDrug FormulationsDrug IndustryEncapsulatedEngineeringEnsureEvaluationFeasibility StudiesFlavoringFoundationsGoalsHospitalsIncentivesIndustryKansasMasksMedical ResearchMedication ErrorsMissouriModelingOral cavityParticle SizePatientsPerformancePharmaceutical PreparationsPharmacologic SubstancePharmacologyPhasePhysician ExecutivesPositioning AttributePrincipal InvestigatorProductionPropertyProteinsProviderResearchShapesSolutionsSurfaceTabletsTaste PerceptionTechniquesTechnologyTestingThickTimeTitrationsUniversitiesWorkbasecapsulecompliance behaviorcontrolled releasedesigndosagedrug developmenteffective therapyexperienceflexibilityimprovedlarge scale productionmeetingsnew technologyparticlepediatric pharmacologyresearch clinical testingsegregationsuccesstechnology developmentuser-friendly
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pediatric drug development presents many unique challenges in the effective treatment of diseases in children, from adequate dosing information and pediatric-specific testing to palatable flavor profiles and effective delivery formats. A novel
technology that masks bitter drug flavors while providing flexibility in dose design and format would enable formulation of existing adult pharmaceutical products into medications specially designed for pediatric patients. Our proposed strategy uses Precision Particle Fabrication (PPF) to develop pediatric drug-loaded microparticles that mask bitter flavors and allow for flexible dosing and formats. The central advantage of PPF technology lies in its precise control of particle size, shape, material, and release rates. Our long-term goal is to adapt this flexible, user-friendly, inexpensive technology to create a platform for microencapsulating unpalatable pediatric active pharmaceutical ingredients (API's). We hypothesize that the uniform, precisely engineered microparticles produced by PPF will create effectively taste- masked formulations for pediatric drugs while also allowing for the swift and controlled release of the active agents under digestive conditions. We further hypothesize that this robust microparticle strategy will allow for accurate, flexible dosing and adaptation to multiple drug delivery formats. Our research team will develop and characterize model bitter API-containing microparticles with precisely controlled physicochemical features that are designed to meet palatability standards (Aim 1). We will then optimize the release characteristics and taste-masking performance of these model microparticles (Aim 2). The result will be model drug-loaded microparticles that meet palatability standards based on particle size, homogeneity, and drug surface concentration and that can be tailored for desired release profiles under digestive conditions. After establishing the feasibility of precisely engineering these microparticles, Phase II will focus on the clinical evaluation of organoleptic properties of taste and mouth feel as well as demonstration of dosing accuracy, titration, and format flexibility. This PPF-based encapsulation strategy addresses issues of palatability, dosage accuracy, and format flexibility in pediatric drugs, while improving upon existing encapsulation techniques that are costly and time-consuming and produce poorly controlled, heterogeneous batches of microparticles. In adition, this PF technology is highly adaptable to multiple drugs and matrix/coating materials as well as large-scale production. The result will be an inexpensive, highly flexible pediatric platform for creating palatable, age-appropriate, and accurate dosage forms, leading to safer pediatric formulations and improved patient compliance.
PUBLIC HEALTH RELEVANCE: Inadequate pediatric pharmaceutical formulations impair effective treatment of diseases in children due to poor compliance, ad hoc formulations, and dangerous medication errors. At the foundation of the problem are palatability, accurate dosing, and age-appropriate dosage format challenges. Development of a user-friendly, inexpensive development platform for pediatric reformulation of existing adult drug products to administer taste-masked active pharmaceutical ingredients (APIs) with controlled release rates is needed. Using model bitter APIs, this project aims to test the feasibility of Precision Particle Fabricatio technology to produce palatable, age-appropriate, and accurate doses as a means to safer pediatric medications and better compliance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preparing BBI-001 as an oral, non-absorbed iron chelator for prevention of iron overload
-
批准号:10258539
-
项目类别:
-
资助金额:$29.94万
-
财政年份:2021
-
负责人:Cory Berkland
-
依托单位:
Precision Particle Fabrication-enabled Betamethasone-loaded Microspheres for Tran
-
批准号:8396087
-
项目类别:
-
资助金额:$28.71万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8433328
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8239401
-
项目类别:
-
资助金额:$35.92万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8607930
-
项目类别:
-
资助金额:$35.96万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Integrative colloidal gels for cranial defect repair
-
批准号:8804184
-
项目类别:
-
资助金额:$29.67万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Targeted nanoscale antigen arrays for treating autoimmune diseases
-
批准号:8513574
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2012
-
负责人:Cory Berkland
-
依托单位:
Multi-day Pain Management Therapy with Novel Injectable Formulation
-
批准号:8198342
-
项目类别:
-
资助金额:$25.37万
-
财政年份:2011
-
负责人:Cory Berkland
-
依托单位:
Expanding Precision Particle Fabrication Technology for the Widespread Control of
-
批准号:7908631
-
项目类别:
-
资助金额:$34.95万
-
财政年份:2010
-
负责人:Cory Berkland
-
依托单位:
Expanding Precision Particle Fabrication Technology for the Widespread Control of
-
批准号:8089561
-
项目类别:
-
资助金额:$34.57万
-
财政年份:2010
-
负责人:Cory Berkland
-
依托单位:
BIODEGRADABLE NANOPARTICLES FOR AIDS GENE THERAPY
-
批准号:7959699
-
项目类别:
-
资助金额:$26.71万
-
财政年份:2009
-
负责人:Cory Berkland
-
依托单位:
BIODEGRADABLE NANOPARTICLES FOR AIDS GENE THERAPY
-
批准号:7720554
-
项目类别:
-
资助金额:$24.61万
-
财政年份:2008
-
负责人:Cory Berkland
-
依托单位:
TRACEABLE CANCER-TARGETED NANOPARTICLES FOR LOCALIZED CHEMOTHERAPY
-
批准号:7609711
-
项目类别:
-
资助金额:$3.35万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
-
批准号:7660520
-
项目类别:
-
资助金额:$6.83万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
-
批准号:7488597
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
BIODEGRADABLE NANOPARTICLES FOR AIDS GENE THERAPY
-
批准号:7609904
-
项目类别:
-
资助金额:$25.24万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
-
批准号:7304759
-
项目类别:
-
资助金额:$6.91万
-
财政年份:2007
-
负责人:Cory Berkland
-
依托单位:
TRACEABLE CANCER-TARGETED NANOPARTICLES FOR LOCALIZED CHEMOTHERAPY
-
批准号:7381090
-
项目类别:
-
资助金额:$6.15万
-
财政年份:2006
-
负责人:Cory Berkland
-
依托单位:
TRACEABLE CANCER-TARGETED NANOPARTICLES FOR LOCALIZED CHEMOTHERAPY
-
批准号:7170249
-
项目类别:
-
资助金额:$1.48万
-
财政年份:2005
-
负责人:Cory Berkland
-
依托单位:
海外基金